Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

NCT01803321 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Juvenile Idiopathic Arthritis

Interventions

DRUG: rilonacept (IL-1 Trap)
OTHER: Placebo

Sponsor

Regeneron Pharmaceuticals